London, United Kingdom
Arix Bioscience, founded in 2015 and headquartered in the United Kingdom, operates at the crossroads of biotechnology, finance, and health care. Famed for its collaborative approach, the company aligns with visionary entrepreneurs to pilot transformative advances in life sciences. The blend of being both institutionally and geographically nimble provides Arix Bioscience with a distinct strategic advantage, facilitating access to high-caliber life science innovations worldwide.
The company made its last significant financial maneuver with a $21.44M Post-IPO Equity investment on 04 April 2018. While specific investor names were not disclosed, the successful raise underscores its credibility in attracting substantial capital for developing game-changing scientific enterprises. Arix Bioscience continues to assertively push the envelope in life sciences, with an unyielding commitment to revolutionizing health care solutions.
